ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death

New England Journal of Medicine

Volumn 369, Issue 6, 2013, Pages 529-539

  Vander Lugt, Mark T ^a   Braun, Thomas M ^b   Hanash, Samir ^c   Ritz, Jerome ^d   Ho, Vincent T ^d   Antin, Joseph H ^d   Zhang, Qing ^c   Wong, Chee Hong ^c   Wang, Hong ^c   Chin, Alice ^c   Gomez, Aurélie ^a   Harris, Andrew C ^a   Levine, John E ^a   Choi, Sung W ^a   Couriel, Daniel ^a   Reddy, Pavan ^a   Ferrara, James L M ^a   Paczesny, Sophie ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLUCOCORTICOID; INTERLEUKIN 1 RECEPTOR TYPE II; LYMPHATIC VESSEL ENDOTHELIAL HYALURONAN RECEPTOR 1; MACROPHAGE MIGRATION INHIBITION FACTOR; METHOTREXATE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; RAPAMYCIN; REGENERATING ISLET DERIVED 3 ALPHA; SUPPRESSION OF TUMORIGENICITY 2 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CONTROLLED STUDY; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SURVIVAL PREDICTION; SURVIVAL TIME; THERAPY RESISTANCE;

EID: 84881256541     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1213299     Document Type: Article

References (38)

1. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010;363:2091-101.
2. Jenq RR, van den Brink MR. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer 2010;10:213-21.
3. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009;373:1550-61.
4. Weisdorf D, Zhang MJ, Arora M, Horowitz MM, Rizzo JD, Eapen M. Graft-versus-host disease induced graft-versusleukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. Biol Blood Marrow Transplant 2012;18:1727-33.
5. Cragg L, Blazar BR, Defor T, et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant 2000;6:441-7.
6. MacMillan ML, Weisdorf DJ, Wagner JE, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002;8:387-94.
7. Bacigalupo A. Management of acute graft-versus-host disease. Br J Haematol 2007;137:87-98. (Pubitemid 46474711)
8. Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012;18:1150-63.
9. Xhaard A, Rocha V, Bueno B, et al. Steroid-refractory acute GVHD: lack of long-term improved survival using new generation anticytokine treatment. Biol Blood Marrow Transplant 2012;18:406-13.
10. Levine JE, Logan B, Wu J, et al. Graft-versus-host disease treatment: predictors of survival. Biol Blood Marrow Transplant 2010;16:1693-9.
11. MacMillan ML, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood 2010;115:5412-7.
12. Westin JR, Saliba RM, De Lima M, et al. Steroid-refractory acute GVHD: predictors and outcomes. Adv Hematol 2011;2011:601953.
13. Saliba RM, Couriel DR, Giralt S, et al. Prognostic value of response after upfront therapy for acute GVHD. Bone Marrow Transplant 2012;47:125-31.
14. Paczesny S, Krijanovski OI, Braun TM, et al. A biomarker panel for acute graft-versus-host disease. Blood 2009;113:273-8.
15. Paczesny S, Braun TM, Levine JE, et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med 2010;2:13ra2.
16. Ferrara JL, Harris AC, Greenson JK, et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood 2011;118:6702-8.
17. Levine JE, Logan BR, Wu J, et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood 2012;119:3854-60.
18. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825-8.
19. Faca V, Coram M, Phanstiel D, et al. Quantitative analysis of acrylamide labeled serum proteins by LC-MS/MS. J Proteome Res 2006;5:2009-18. (Pubitemid 44232714)
20. Faca V, Pitteri SJ, Newcomb L, et al. Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes. J Proteome Res 2007;6:3558-65. (Pubitemid 47522747)
21. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
22. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21.
23. Robin M, Porcher R, de Castro R, et al. Initial liver involvement in acute GVHD is predictive for nonrelapse mortality. Transplantation 2009;88:1131-6.
24. MacMillan ML, DeFor TE, Weisdorf DJ. What predicts high risk acute graft-versus-host disease (GVHD) at onset? Identification of those at highest risk by a novel acute GVHD risk score. Br J Haematol 2012;157:732-41.
25. Paczesny S. Discovery and validation of graft-versus-host disease biomarkers. Blood 2013;121:585-94.
26. De Gruttola VG, Clax P, DeMets DL, et al. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health workshop. Control Clin Trials 2001;22:485-502. (Pubitemid 32907433)
27. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011;117:3720-32.
28. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005;23:479-90. (Pubitemid 41587888)
29. Yanagisawa K, Naito Y, Kuroiwa K, et al. The expression of ST2 gene in helper T cells and the binding of ST2 protein to myeloma-derived RPMI8226 cells. J Biochem 1997;121:95-103. (Pubitemid 27068281)
30. Löhning M, Stroehmann A, Coyle AJ, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci U S A 1998;95:6930-5. (Pubitemid 28278084)
31. Xu D, Chan WL, Leung BP, et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 1998;187:787-94. (Pubitemid 28115194)
32. Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y. Expression and function of the ST2 gene in a murine model of allergic airway inflammation. Clin Exp Allergy 2002;32:1520-6. (Pubitemid 35278923)
33. Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 2007;282:26369-80. (Pubitemid 47443815)
34. Kurowska-Stolarska M, Kewin P, Murphy G, et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol 2008;181:4780-90. [Erratum, J Immunol 2008;181:8170.]
35. Rössler U, Thomassen E, Höltner L, Baier S, Danescu J, Werenskiold AK. Secreted and membrane-bound isoforms of T1, an orphan receptor related to IL-1-binding proteins, are differently expressed in vivo. Dev Biol 1995;168:86-97.
36. Kumar S, Tzimas MN, Griswold DE, Young PR. Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli. Biochem Biophys Res Commun 1997;235:474-8. (Pubitemid 27326503)
37. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007;117:1538-49. (Pubitemid 46871338)
38. Jagasia M, Arora M, Flowers ME, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012;119:296-307.